Aligos Therapeutics Inc
ALGS
NASDAQ
Biotechnology
$6.89
USD
+0.12 (+1.77%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $42.28M
Volume 66.7K
Revenue
$4.71M
TTM
+43.9%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-90.32M
TTM
-69.6%
YoY
Operating Cash Flow
$-84.72M
TTM
-7.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.3 | 1.0 | 0.7 | 0.2 | 2.8 |
YoY Growth | -68.5% | -9.0% | -41.6% | -73.1% | +810.0% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.3 | 1.0 | 0.7 | 0.2 | 2.8 |
Selling, General & Administrative | 5.1 | 5.6 | 5.2 | 4.9 | 6.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 19.6 | 19.5 | 29.1 | 22.0 | 29.8 |
Operating Income | -19.2 | -18.6 | -28.4 | -21.8 | -26.9 |
EBITDA | -19.0 | -18.3 | -28.1 | -21.6 | -26.6 |
Other Income / Expense | 61.5 | 2.9 | -3.1 | 2.0 | 3.4 |
Total Other Income / Expense | 62.4 | 2.9 | -3.1 | 2.0 | 4.2 |
Income Before Income Taxes | 43.1 | -15.7 | -31.5 | -19.9 | -22.7 |
Income Taxes | 0.0 | 0.2 | 0.1 | 0.0 | 0.3 |
Net Income | 43.1 | -15.9 | -31.5 | -19.9 | -23.0 |
Consolidated Net Income / Loss | 43.1 | -15.9 | -31.5 | -19.9 | -23.0 |
Net Income Attributable to Common Shareholders | 43.1 | -15.9 | -31.5 | -19.9 | -23.0 |
Basic EPS | $5.12 | -$1.53 | -$3.04 | -$1.91 | -$2.21 |
Diluted EPS | -$2.11 | -$1.53 | -$3.04 | -$1.97 | -$2.21 |
Basic Shares Outstanding | 8.4M | 10.4M | 10.4M | 10.4M | 10.4M |
Diluted Shares Outstanding | 8.7M | 10.4M | 10.4M | 10.1M | 10.4M |